Saruta T
Am J Med. 1984 Feb 27;76(2A):117-21. doi: 10.1016/0002-9343(84)90969-0.
The introduction of the western diet and lifestyle to Japan has been associated with changes in body build, lipid levels, and disease pattern. An increased incidence of coronary heart disease parallels increased fat intake. Thiazide diuretics and beta blockers may have adverse effects on blood lipids in man leading to an increase in the risk of coronary heart disease; therefore, for many patients these drugs may not offer the optimum treatment strategy. Hence, prazosin, a drug that effectively lowers blood pressure without adversely affecting lipid metabolism, has been evaluated in nine studies within Japan. Prazosin showed adequate antihypertensive effects even at doses as low as 1 to 3 mg per day. Sustained constant blood pressure reductions were achieved with maintenance doses of 3 to 6 mg per day without significant side effects. Even when given in low doses, prazosin increased high-density lipoprotein cholesterol while inhibiting elevations of total cholesterol and decreasing triglycerides. In view of these findings, prazosin as a single agent can be considered for monotherapy of hypertension.
西方饮食和生活方式引入日本后,人们的体型、血脂水平和疾病模式都发生了变化。冠心病发病率的上升与脂肪摄入量的增加同步。噻嗪类利尿剂和β受体阻滞剂可能对人体血脂产生不利影响,从而增加患冠心病的风险;因此,对许多患者来说,这些药物可能并非最佳治疗策略。因此,日本已在9项研究中对哌唑嗪进行了评估,该药物能有效降低血压,且不会对脂质代谢产生不利影响。哌唑嗪即使在每天1至3毫克的低剂量下也显示出足够的降压效果。每天3至6毫克的维持剂量可实现血压持续稳定下降,且无明显副作用。即使低剂量给药,哌唑嗪也能增加高密度脂蛋白胆固醇,同时抑制总胆固醇升高并降低甘油三酯。鉴于这些发现,哌唑嗪可作为单一药物用于高血压的单一疗法。